

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10727.012	
	Filing Date	2 December 2003	
	First Named Inventor	Peter C.R. EMTAGE	
	Art Unit	1600 1031	
	Examiner Name		
Total Number of Pages in This Submission	5	Attorney Docket Number	NUVO-02CP

RECEIVED
CENTRAL FAX CENTER

MAR 02 2004

OFFICIAL

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO-1449 (2 pages).
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Renea S. Polizotto, Ph.D.
Signature	<i>Renea S. Polizotto</i>
Date	2 March 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Donna B. Rose		
Signature	<i>Donna B. Rose</i>	Date	2 March 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT
Docket No.: NUVO-02CP

RECEIVED
CENTRAL FAX CENTER

MAR 02 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF TRANSMISSION
UNDER 37 CFR 1.8

OFFICIAL

Applicant(s): Emtage et al.

Serial No: 10/727,012

Filed: December 12, 2003

For: METHODS OF THERAPY AND
DIAGNOSIS USING TARGETING
OF CELLS THAT EXPRESS
KILLER CELL
IMMUNOGLOBULIN-LIKE
PROTEIN

I hereby certify that this correspondence is being
facsimile transmitted to facsimile no. 703.872.9305 and
is addressed to Attn.: Group Art Unit 1600,
Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450.

Date of Deposit: March 2, 2004

Name of Person Mailing: Donna B. Rose


Signature of Person Mailing

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. 1.56, 1.97 AND 1.98

Attn.: Group Art Unit 1600
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the attached form PTO-1449 is hereby submitted by Applicants in connection with the above-identified application. Pursuant to 37 C.F.R. §1.98(d), copies of the documents B1 and C1-C18 cited on the PTO-1449 are not provided because they were previously submitted to the U.S. Patent and Trademark Office in parent applications, U.S. Serial No. 09/363,316 filed July 28, 1999 and U.S. Serial No. 10/414,539 filed April 14, 2003, from which priority is claimed under 35 U.S.C. §120. However, copies of these documents will be resubmitted at the Examiner's request.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein constitutes prior art under 35 U.S.C. § 102 or § 103.

PATENT
Docket No.: NUVO-02CP

In accordance with 37 C.F.R. §1.98(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. §1.98 and the Examiner is respectfully requested to consider the listed references.

No fee is believed due under 37 C.F.R. §1.97(b) because this statement and Form PTO-1449 are being submitted before receipt of the first office action based on the merits of the above-identified patent application. However, the Commissioner is hereby authorized to charge payment of any additional fees due or credit any overpayment to Deposit Account No. 501169.

Respectfully submitted,

Date: March 2, 2004

By: Renée S. Polizotto
Renée S. Polizotto, Ph.D.
Agent for Applicants
Reg. No. 53,474
Customer No. 34285
NUVELO, INC.
675 Almanor Avenue
Sunnyvale, CA 94085
Tel.: (408) 215.4000
Fax: (408) 524.8145

SHEET 1 of 2

Form PTO-1449 (Modified)	U.S. Department of Patent and Trademark	App. Docket No. NUVO-02CP	Serial No. 10/727,012
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Emtage, et al.	
		Filing Date 12/02/2003	Group Not yet assigned

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS								
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	EP 0 897 981 A1	02/24/99	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C1	Behr <i>et al.</i> , Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy," <i>Int. J. Cancer</i> 77:787-795 (1988).
	C2	Borges and Cosman, "LIRs/ILTs/MIRs, inhibitory and stimulatory Ig-superfamily receptors expressed in myeloid and lymphoid cells," <i>Cytokine and Growth Factor Reviews</i> 11:209-217 (2000).
	C3	Clark <i>et al.</i> , "The gene encoding the immunoregulatory signaling molecule CMRF-35A localized to human chromosome 17 in close proximity to other members of the CMRF-35 family," <i>Tissue Antigens</i> 57:415-423 (2001).
	C4	De Maria <i>et al.</i> , "Expression of HLA class I-specific inhibitory natural killer cell receptors in HIV-specific cytolytic T lymphocytes: Impairment of specific cytolytic functions," <i>Proc. Natl. Acad. Sci. USA</i> 94:10285-10288 (1997).
	C5	Fournier <i>et al.</i> , "FDF03, a novel inhibitory receptor of the immunoglobulin superfamily, is expressed by human dendritic and myeloid cells," <i>J. Immunol.</i> 165:1197-1209 (2000).
	C6	Held <i>et al.</i> , "The NK cell receptor repertoire: formation, adaptation and exploitation," <i>Curr. Opin. Immunol.</i> 15:233-237 (2003).
	C7	Hornick <i>et al.</i> , "Chimeric CLL-1 Antibody Fusion Proteins Containing Granulocyte-

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>	

SHEET 2 of 2

Form PTO-1449 (Modified) U.S. Department of Patent and Trademark INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Atty. Docket No. NUVO-02CP	Serial No. 10/727,012
	Applicant Emtage, et al.	
	Filing Date 12/02/2003	Group Not yet assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
		Macrophage Colony-Stimulating Factor or Interleukin-2 With Specificity for B-Cell Malignancies Exhibit Enhanced Effector Functions While Retaining Tumor Targeting Properties," <i>Blood</i> 89:4437-4447 (1997).
	C8	Jiang and Moller, "In vitro effects of HgCl ₂ on murine lymphocytes. I. Preferable activation of CD4+ T cells in a responder strain," <i>J. Immunol.</i> 154:3138-3146 (1995).
	C9	Larson, "Current use and future development of gemtuzumab ozogamicin," <i>Semin. Hematol.</i> 38 (Suppl. 6):24-31 (2001).
	C10	Martin <i>et al.</i> , "CD84 functions as a homophilic adhesion molecule and enhances IFN- γ secretion: Adhesion is mediated by Ig-like domain 1," <i>J. Immunol.</i> 167:3668-3676 (2001).
	C11	Ota <i>et al.</i> , "The application of immunotargeting into cancer chemotherapy with carboplatin: in vitro and in vivo studies," <i>Asia-Oceania J. Obstet. Gynaecol.</i> 19:449-457 (1993).
	C12	Ozaki <i>et al.</i> , "Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24," <i>Blood</i> 90:3179-3186 (1997).
	C13	Salmon-Divon <i>et al.</i> , "Generation of the natural killer cell repertoire: the sequential vs. the two-step selection model," <i>Bull. Math. Biol.</i> 65:199-218 (2003).
	C14	Simpson <i>et al.</i> , "Retinal VEGF mRNA measured by SYBR Green I fluorescence: A versatile approach to quantitative PCR," <i>Molec. Vision</i> 6:178-183 (2000).
	C15	Speckman <i>et al.</i> , "Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility," <i>Hum. Genet.</i> 112:34-41 (2003).
	C16	Sprenger <i>et al.</i> , "Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer," <i>Cancer Res.</i> 59:2370-2373 (1999).
	C17	Tai <i>et al.</i> , "CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells," <i>Blood</i> 99:1419-1427 (2002).
	C18	Yang <i>et al.</i> , "Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferators, perfluorooctanoic acid," <i>Int. Immunopharm.</i> 2:389-397 (2002).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	